Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast Cancer

Kevin Kalinsky, MD
Published: Wednesday, Jan 11, 2017



Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

Ruxolitinib, a JAK2 inhibitor, was given in combination with trastuzumab to patients who have progressed on trastuzumab. This non-chemotherapy regimen is taken orally, familiar to patients previously who were treated with trastuzumab.

Results showed the combination was well tolerated without any observable toxicities. A multi-centered phase II trial is ongoing.
 


Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

Ruxolitinib, a JAK2 inhibitor, was given in combination with trastuzumab to patients who have progressed on trastuzumab. This non-chemotherapy regimen is taken orally, familiar to patients previously who were treated with trastuzumab.

Results showed the combination was well tolerated without any observable toxicities. A multi-centered phase II trial is ongoing.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x